Atlas - A Handheld High Resolution Wide-field Retinal Imager

7.项目摘要 早产儿视网膜病变（ROP）是一种可治疗的眼病， 出生体重<1500 g或胎龄<30周。美国每年有28,000名婴儿出生， 发展ROP的风险。然而，即使有先进的治疗方法，这些婴儿中的400至600人- 每年都失明。在全球范围内，有5万多例记录在案的可预防儿童病例 因ROP而失明。因此，世界卫生组织宣布ROP是视力障碍的主要原因， 对儿童的伤害。这些高数字可以主要归因于这些婴儿的筛查不足 部分原因是接受过儿科培训的眼科医生数量少， 重症监护室（NICU）。最近的研究表明，广角视网膜摄影的远程筛查 结合早期治疗实践可能是一种经济上可行的，节省成本的措施， 证明了目前对ROP的护理标准，防止了许多不必要的失明病例。 在该应用中，RetiVue LLC建议开发Atlas，这是一种低成本（<5，000美元的市场成本），高分辨率， 这是一种能够对视网膜进行宽视野成像的手持式设备，可轻松诊断和筛查ROP。 我们独特的设计方法利用弗吉尼亚大学开发的新型视网膜成像技术 这使得能够实现能够捕获120 °视网膜视野的极低成本的设备，其可以在远程中找到用途， 视网膜ROP筛查程序。利用这项技术，我们将首先设计一个广角物镜透镜 该模块能够提供婴儿视网膜的连续照明的120 °视图。该透镜模块将 设计成使得接触表面将与人体的独特解剖结构物理相容， 婴儿的眼睛和周围的面部骨骼结构。然后将构建一个阿尔法原型， 利用具有用于图像的定制固件的普通消费者数码相机来光栅物镜透镜模块 捕获.阿特拉斯原型将强调一个轻量级（<1.25磅）的设计与紧凑，手持形式 因子 在第一阶段应用期间完成的工作以及随后的临床试验将奠定技术基础。 在此基础上，世界上第一个制造简单、价格合理、高度便携且易于使用的 ROP筛选装置可以商品化。我们希望这种高度破坏性的设备可以帮助克服 建立成功的ROP远程筛查的主要经济和技术障碍， 在发达国家和发展中国家的NICU中，

7. Project Summary Retinopathy of prematurity (ROP) is a treatable eye disease which affects the vision of neonatal infants with a birth weight of <1500g or gestational age of <30 weeks. There are 28,000 infants born each year in the US at risk for developing ROP. However, even with advanced treatments available 400 to 600 of these infants be- come blind each year. Globally, there are more than 50,000 documented cases of preventable childhood blindness due to ROP. The World Health Organizataion has thus declared ROP a leading cause of vision im- pairment in children. These high numbers can be primarily attributed to inadequate screening of these infants due in part to the low numbers of pediatric-trained ophthalmologists and ROP diagnostic equipment in neonatal intensive care units (NICUs). Recent studies suggest that tele-screening with wide-angle retinal photography in combination with early treatment practices may be an economically feasible, cost-saving measure for im- proving the current standard of care for ROP, preventing many cases of needless blindness. In this application, RetiVue LLC proposes to develop the Atlas, a low cost (<$5,000 market cost), high resolu- tion, hand-held device capable of wide-field imaging of the retina for easily diagnosing and screening for ROP. Our unique design approach leverages novel retinal imaging technology developed at the University of Virginia that enables an extremely low cost device capable of capturing a 120¿ retinal field which may find use in tele- retinal ROP screening programs. Using this technology, we will first engineer a wide-angle objective lens module capable of providing a continuously illuminated 120¿ view of the infant retina. This lens module will be designed such that the contacting surface will be physically compatible with the unique anatomical structure of the infant eye and surrounding facial bone structure. An alpha-prototype will then be constructed which inte- grates the objective lens module with a common consumer digital camera with customized firmware for image capture. The Atlas prototype will emphasize a lightweight (<1.25lbs) design with a compact, hand-held form factor. Work completed during this Phase I application in addition to subsequent clinical testing will lay the technical foundation onto which the world's first simple-to-manufacture, affordable, highly portable, and easy-to-use ROP screening device can be commercialized. We hope that this highly disruptive device can help overcome the primary economic and technological access barriers to establishing successful ROP tele-screening pro- grams within NICUs in developed and developing countries alike.